- · Acquiring a medical practice in Switzerland requires three distinct cantonal authorizations, not a single federal clearance.
- · Physician quotas under the Höchstzahlenverordnung can block a transaction entirely, even after all operational criteria are satisfied.
- · Approval timelines of 4–12 weeks are the baseline; quota complications can extend this significantly and pressure deal closing schedules.
- · Compliance is activity-based, not transaction-based, meaning the burden falls on the buyer's ongoing operational capability, not on deal structure or price.
Switzerland's healthcare sector projects an orderly face to the outside world. Federal legislation, the Bundesgesetz über die Krankenversicherung (KVG), establishes a coherent national baseline for health insurance and professional standards. For a buyer approaching a Swiss medical practice acquisition, the statutory landscape can appear manageable. That impression tends not to survive first contact with cantonal administration.
The KVG, specifically Articles 36 and 37, sets the foundational requirements for physician practice rights and billing authorization. What the federal framework does not do is consolidate approvals into a single authority. Each of Switzerland's 26 cantons independently administers the licensing regime applicable to healthcare practice operations within its borders. The cantonal health directorate (often the Kantonsarzt or Hauptabteilung Gesundheit, depending on the canton) is the relevant gatekeeper, and it operates with a degree of procedural independence that buyers accustomed to centralized licensing regimes frequently underestimate.
A buyer acquiring a medical practice in Switzerland must obtain three legally distinct authorizations, each with its own application form, documentation set, and review timeline.
The first is the professional practice license (Berufsausübungsbewilligung), issued by the cantonal health directorate to the individual practitioner. This confirms that the physician meets the professional qualifications required to practice independently within the canton. It is person-specific, not entity-specific.
The second authorization becomes relevant when the practice operates under a legal entity — an AG or GmbH — rather than under the direct name of a licensed physician. In this structure, the buyer must obtain a separate operating permit (Betriebsbewilligung als ambulante ärztliche Einrichtung). Zurich Canton, for instance, distinguishes clearly between individual practitioner operations and institutional medical entities, issuing separate operating permits for the latter. The Zurich Merkblatt for ambulatory medical institution operating permits, updated as recently as September 2024, outlines a documentation requirement set that is substantively different from what applies to a solo practitioner filing. Buyers structuring acquisitions through corporate vehicles should treat this not as an administrative footnote but as a parallel approval track requiring early engagement.
The third authorization is the OKP/LAMal billing right (Zulassung zur Tätigkeit zulasten der obligatorischen Krankenpflegeversicherung). Without this, a practice cannot bill the compulsory health insurance system — which, for most general and specialist practices, represents the majority of revenue. Glarus Canton, for example, publishes a specific Merkblatt for OKP admission with its own documentation checklist. Lucerne maintains a distinct application procedure for ambulatory medical institution billing authorization. Neither mirrors the other. There is no national template.
The practical consequence is that a buyer, and their legal advisors, must run three parallel processes with three separate cantonal authorities, each operating on its own timeline. The conventional 4–12 week window cited for cantonal approvals is the baseline under normal conditions. It does not account for incomplete submissions, requests for supplementary documentation, or the considerably more disruptive complication that follows.
Perhaps the most underappreciated structural risk in Swiss healthcare M&A is the physician quota system under the Höchstzahlenverordnung. Federal law, via Article 55a KVG, authorizes cantons to impose maximum numbers of billing-eligible independent practitioners in ambulatory settings, segmented by region and medical specialty. The policy rationale is cost containment within the compulsory insurance system. The transactional consequence is that a canton may lawfully refuse to grant an OKP billing authorization simply because the applicable quota has been reached, regardless of whether the buyer has satisfied every other professional and operational requirement.
Canton Schwyz provides a well-documented illustration of this framework. Its ordinance on physician admission and maximum numbers explicitly regulates both the admission procedure and the applicable caps per service region and specialty. When a quota is saturated, new approvals are blocked. Practice transfers do not automatically inherit the prior operator's billing slot; the incoming practitioner must qualify for a new authorization in their own right. If no slot is available, no authorization is issued.
This creates a due diligence obligation that sits upstream of the standard operational review. Before a buyer commits to a term sheet, the quota position for the relevant specialty and region must be verified with the relevant cantonal authority. A practice may be operationally sound, commercially attractive, and professionally well-run. If the canton's quota for that specialty is at capacity, the economic rationale for the acquisition may be structurally impaired before any legal fees have been invoiced.
The waiting list dynamic compounds the timeline risk. Some cantons maintain quota waiting lists, meaning a buyer may be able to secure a future position but cannot close and operate within a commercially viable window. In financial projections, this variable is routinely omitted from early-stage modelling — a gap that tends to surface at precisely the moment when deal momentum creates pressure to proceed regardless.
The absence of a single national template is not merely a procedural inconvenience. It represents a genuine variable in transaction structuring. Consider the contrast across a handful of cantons.
Glarus publishes a dedicated practice takeover form (Formular Praxisübernahme) with specific documentation requirements for succession scenarios. Zurich applies a dual-track permitting regime, distinguishing individual and institutional operators with different evidentiary standards for each. Lucerne separates the operating permit application from the OKP billing authorization application with procedurally distinct filing requirements. None of these cantons uses the same template as the others. A buyer active across multiple cantons, or advising clients on transactions in unfamiliar cantons, cannot assume that a process that worked in one jurisdiction will translate cleanly to another.
The implication for deal preparation is direct. Cantonal authority engagement should occur in the pre-LOI phase, not post-signing. Early verification of quota availability, form requirements, and expected review timelines informs not only the regulatory work plan but also representations and warranties discussions, closing conditions, and the practical question of whether the transaction is executable at all within the contemplated timeframe.
One structural feature of Swiss healthcare regulation that distinguishes it materially from sector-specific M&A frameworks in other jurisdictions is that the regulatory regime is entirely activity-based. Switzerland has no federal statute governing M&A transactions in healthcare specifically. No transaction notification requirement exists at the federal level for practice transfers. No purchase price or deal structure triggers a healthcare-specific regulatory review.
What the system does require is that whoever operates the practice following a transfer satisfies the cantonal standards for ongoing professional, operational, and billing-authorization compliance. The compliance burden is therefore prospective and operational, not historical and transactional. This is a meaningful distinction. It means that a seller's clean regulatory history provides no guarantee of smooth transition. It also means that buyers who approach the regulatory process as a closing condition rather than a pre-closing priority may find themselves managing authorization gaps in the post-closing period, during which the practice's revenue-generating capacity may be constrained.
For buyers and their advisors, the key takeaway from the cantonal approval architecture is that sequencing matters as much as the substance of any individual application. The professional practice license, the operating permit, and the OKP billing authorization are interdependent but procedurally sequential in most cantons. Submitting them in the wrong order, or without verifying quota availability first, can produce delays that cascade across the entire approval timeline.
A disciplined pre-transaction regulatory audit — covering quota status, applicable forms, and authority-specific timelines for the relevant canton — is the appropriate starting point for any healthcare practice acquisition in Switzerland. This is not a task that benefits from being deferred to the legal due diligence phase. The regulatory findings from that audit should inform the deal structure, the closing timeline, and the risk allocation between buyer and seller before heads of terms are exchanged.
The cantonal approval maze is navigable. It simply requires that buyers and advisors enter it with a complete map, preferably before committing to the journey.
This post reflects publicly available regulatory information as a market observation and does not constitute legal or investment advice. Buyers and sellers should engage qualified legal counsel with canton-specific expertise prior to undertaking any healthcare practice transaction in Switzerland.
